U.S. Markets close in 58 mins.

Alseres Pharmaceuticals, Inc. (ALSE)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
50.000.00 (0.00%)
As of 11:57AM EDT. Market open.
People also watch
ADLSAMARCAPSKDUSAVXT

Alseres Pharmaceuticals, Inc.

275 Grove Street
Suite 2-400
Auburndale, MA 02466
United States
617-419-3289
http://www.alseres.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees3

Key Executives

NameTitlePayExercisedAge
Mr. Peter G. SavasExec. Chairman and Chief Exec. Officer401.62kN/A69
Mr. Kenneth L. Rice Jr., J.D., LLM, MBACFO, Principal Accounting Officer, Exec. VP of Fin. & Admin, Sec. and In-House Counsel267.75kN/A62
Mr. Sam MartinDirector of Fin. and Corp. ComplianceN/AN/AN/A
Amounts are as of December 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Corporate Governance

Alseres Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.